Kalaris Therapeutics, Inc. (KLRS) Income Statement
KLRS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsKLRS revenue and net income
KLRS profit margins
KLRS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KLRS quarterly EPS vs estimates
Kalaris Therapeutics beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.51).
KLRS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $165,000 | $1.1M |
| Cost of revenue | $13,000 | — | — | — | $1.1M | $73,000 | — | — |
| Gross profit | −$13,000 | — | — | — | −$1.1M | −$73,000 | — | — |
| Research & development | $30.8M | $12.3M | $11.7M | $11.8M | $119.6M | $49.6M | $16.2M | $1.7M |
| Sales, general & admin | $15.4M | $6.7M | $1.8M | $2.2M | — | — | — | — |
| Total operating expenses | $46.1M | $55.3M | $13.5M | $14.0M | $168.7M | $71.2M | $26.8M | $4.7M |
| Operating income | −$46.2M | −$55.3M | −$13.5M | −$14.0M | −$169.8M | −$71.3M | −$26.7M | −$3.6M |
| Interest expense | $1.4M | $2.7M | $687,000 | $235,000 | — | — | — | — |
| Income before taxes | −$43.4M | −$58.8M | −$14.7M | −$15.5M | −$171.0M | −$69.8M | −$23.8M | −$2.4M |
| Income taxes | — | — | — | — | $1.0M | — | — | — |
| Net income | −$43.4M | −$58.8M | −$14.7M | −$15.5M | −$172.0M | −$69.8M | −$23.8M | −$2.4M |
| EBITDA | −$42.0M | −$58.8M | −$14.0M | −$15.2M | −$169.8M | −$69.7M | −$23.8M | −$2.4M |
| EPS (diluted) | −$4.21 | −$4.41 | −$1.83 | −$2.20 | −$2.74 | −$5.54 | −$8.42 | — |
| Operating margin | — | — | — | — | — | — | −16,182.4% | −316.8% |
| Net margin | — | — | — | — | — | — | −14,447.9% | −214.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $10,000 | $10,000 | — | — | — | — | — | — | — | — | $3.6M |
| Gross profit | — | −$10,000 | −$10,000 | — | — | — | — | — | — | — | — | −$3.6M |
| Research & development | $9.0M | $7.6M | $7.2M | $9.1M | $8.4M | $6.0M | $320,000 | $36.0M | $3.2M | $2.0M | $3.0M | $30.5M |
| Sales, general & admin | $3.4M | $4.3M | $3.6M | $3.6M | $3.8M | $4.3M | $3.3M | $1.8M | $976,000 | $602,000 | $498,000 | — |
| Total operating expenses | $12.4M | $11.8M | $10.8M | $12.7M | $12.3M | $10.4M | $19.5M | $37.8M | $4.2M | $2.6M | $3.5M | $43.3M |
| Operating income | −$12.4M | −$11.8M | −$10.8M | −$12.7M | −$12.3M | −$10.4M | −$19.5M | −$37.8M | −$4.2M | −$2.6M | −$3.5M | −$47.0M |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $1.4M | $1.3M | $815,000 | $499,000 | $78,000 | $39,000 | — |
| Income before taxes | −$11.5M | −$10.9M | −$10.0M | −$11.9M | −$11.3M | −$10.2M | −$18.3M | −$38.1M | −$5.7M | −$3.4M | −$3.5M | −$44.3M |
| Net income | −$11.5M | −$10.9M | −$10.0M | −$11.9M | −$11.3M | −$10.2M | −$18.3M | −$38.1M | −$5.7M | −$3.4M | −$3.5M | −$44.3M |
| EBITDA | −$12.4M | −$10.8M | −$10.0M | −$11.9M | −$11.3M | −$8.8M | −$18.3M | −$37.3M | −$5.2M | −$3.3M | −$3.4M | −$40.6M |
| EPS (diluted) | −$0.48 | −$0.46 | −$0.44 | −$0.64 | −$0.61 | −$2.52 | −$3.28 | −$0.82 | −$0.05 | −$0.26 | −$0.52 | −$0.39 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KLRS's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KLRS financial results
Kalaris Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $43.4 million. Diluted earnings per share came to −$4.21.
See the KLRS stock overview for the latest quote and news, or the KLRS chart for price history and technical indicators.
KLRS income statement FAQ
Does Kalaris Therapeutics have revenue?
Kalaris Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Kalaris Therapeutics profitable?
No. Kalaris Therapeutics reported a net loss of $43.4 million in fiscal 2025.
How much does Kalaris Therapeutics spend on research and development?
Kalaris Therapeutics spent $30.8 million on research and development in fiscal 2025.
What are Kalaris Therapeutics's earnings per share?
Kalaris Therapeutics earned $-4.21 per diluted share in fiscal 2025, compared with $-4.41 a year earlier.
When will Kalaris Therapeutics report its next earnings?
Kalaris Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Kalaris Therapeutics's fiscal year end?
Kalaris Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.